Scientific Publications

Scientific publications on subjects and technologies related to Diamyd Medicals research and activities.

The burden of Diabetes

IDF Diabetes Atlas

Modeling the Total Economic Value of Novel Type 1 Diabetes (T1D) Therapeutic Concepts
JDRF T1D Fund, Health Advances

State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Diabetes Technol Ther. 2019 Feb;21(2):66-72

Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study
Lancet. 2018 Aug 11;392(10146):477-486

Novel subgroups of adult-onset diabetes and their association
Lancet Diabetes Endocrinol. 2018 May;6(5):361-369

Economic Costs of Diabetes in the U.S. in 2017
Diabetes Care. 2018 May;41(5):917-928

Impact of C-Peptide Preservation on Metabolic and Clinical Outcomes in the Diabetes Control and Complications Trial
Diabetes. 2014 Feb;63(2):739-48

Type 1 diabetes
Lancet. 2014 Jan 4;383(9911):69-82

Immunotherapy with Diamyd^® (GAD65)

Intralymphatic GAD-Alum (Diamyd^®) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2
J Clin Endocrinol Metab. 2022 Aug 18;107(9):2644-2651.

Association between treatment effect on C-peptide preservation and HbA1c in meta-analysis of glutamic acid decarboxylase (GAD)-alum immunotherapy in recent-onset type 1 diabetes
Diabetes Obes Metab. 2022 Aug;24(8):1647-1655.

Antigen-based Immunotherapy Improves Glycemic Metrics and β-Cell Function
J Clin Endocrinol Metab. 2022 Jul 26;dgac437.

Long-Term GAD-alum Treatment Effect on Different T-Cell Subpopulations in Healthy Children Positive for Multiple Beta Cell Autoantibodies
J Immunol Res. 2022 May 25;2022:3532685.

Intralymphatic Glutamic Acid Decarboxylase With Vitamin D Supplementation in Recent-Onset Type 1 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial
Diabetes Care. 2021 Jul;44(7):1604-1612.

Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes
Diabetologia volume 63, pages2177–2181(2020)

Intralymphatic Glutamic Acid Decarboxylase-Alum Administration Induced Th2-Like-Specific Immunomodulation in Responder Patients: A Pilot Clinical Trial in Type 1 Diabetes
J Diabetes Res. 2018 May 24;2018:9391845

More on Intralymphatic Injection of Autoantigen in Type 1 Diabetes
N Engl J Med. 2017 Jul 27;377(4):403

Intralymphatic Injection of Autoantigen in Type 1 Diabetes
N Engl J Med. 2017 Feb 16;376(7):697-699

GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-analysis
Diabetologia. 2017 Jan;60(1):43-49

Beta cell regeneration with Remygen^® (GABA)

A Clinically Applicable Positive Allosteric Modulator of GABA Receptors Promotes Human β-Cell Replication and Survival as well as GABA’s Ability to Inhibit Inflammatory T Cells
Journal of Diabetes Research. 2019; 2019:5783545

Clinically applicable GABA receptor positive allosteric modulators promote ß-cell replication
Sci Rep. 2017 Mar 23;7(1):374

Long-Term GABA Administration Induces Alpha Cell-Mediated Beta-like Cell Neogenesis
Cell. 2017 Jan 12;168(1-2):73-85

Study of GABA in Healthy Volunteers: Pharmacokinetics and Pharmacodynamics
Front Pharmacol. 2015 Nov 10;6:260

Oral Treatment with c-Aminobutyric Acid Improves Glucose Tolerance and Insulin Sensitivity by Inhibiting Inflammation in High Fat Diet-Fed Mice
PLoS One. 2011;6(9):e25338

Order GAD for preclinical research

ORDER

©

Privacy Policy | Cookie Policy | Expanded Access Policy

Share This Page

GAD PRODUCTS

Order GAD for preclinical research